Condition: Type 2 Diabetes (Adult Onset) · Sponsor: The University of Texas Health Science Center at San Antonio
The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.
This description comes directly from the study's public registry record.
Muhammad Abdul-Ghani, MD · 210-567-6691 · abdulghani@uthscsa.edu
Gozde Baskoy, PhD · 210-358-7200 · baskoy@uthscsa.edu
Always discuss trial participation with your own doctor first.
| University Health System Texas Diabetic Institute | San Antonio, Texas, United States | Recruiting |
| UT Health Science Center | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06246799